Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (MIRM) will participate in upcoming investor conferences, including Leerink Partners Global Biopharma Conference 2024 and Barclays Global Healthcare Conference 2024. The company aims to showcase its novel therapies for rare diseases.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

• Leerink Partners Global Biopharma Conference 2024 on Tuesday March 12, 2024
  • Company presentation - Tuesday, March 12 starting at 3:00 p.m. ET
• Barclays Global Healthcare Conference 2024 on Wednesday March 13, 2024

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305551076/en/

Investor Contacts:

Andrew McKibben

investors@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

When will Mirum Pharmaceuticals participate in the Leerink Partners Global Biopharma Conference 2024?

Mirum Pharmaceuticals will participate in the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024.

What time will Mirum Pharmaceuticals start its company presentation at the Leerink Partners Global Biopharma Conference 2024?

Mirum Pharmaceuticals will start its company presentation at the Leerink Partners Global Biopharma Conference 2024 at 3:00 p.m. ET on Tuesday, March 12, 2024.

Which upcoming investor conference will Mirum Pharmaceuticals participate in after the Leerink Partners Global Biopharma Conference 2024?

Mirum Pharmaceuticals will participate in the Barclays Global Healthcare Conference 2024 on Wednesday, March 13, 2024.

Where can investors find webcast links and additional information about Mirum Pharmaceuticals' participation in the conferences?

Investors can visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.